Dapagliflozin Cancer Signal Weighs Heavily In FDA Panel's Negative Vote

The Endocrinologic and Metabolic Drugs Advisory Committee votes 9-6 against approval of the first-in-class SGLT-2 inhibitor, with panelists citing the need for more pre-approval data on the risk of bladder and breast cancer with the diabetes drug.